视网膜静脉阻塞并发黄斑水肿的联合药物治疗进展
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Combination pharmacotherapy for macular edema associated with retinal vein occlusion
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    视网膜静脉阻塞(retinal vein occlusion,RVO)是除糖尿病视网膜病变外最常见的视网膜血管疾病,黄斑水肿(macular edema,ME)是RVO的常见并发症,是导致视力下降的主要原因。黄斑水肿的产生被认为与静脉阻塞以后缺血缺氧诱导的血管内皮生长因子(vascular endothelial growth factor,VEGF)以及炎症因素导致的血-视网膜屏障破坏相关,因此目前临床上主要采用玻璃体腔内注射抗VEGF药物或皮质类固醇药物的治疗方式。由于这两种药物作用机制、药效持续时间、不良反应以及价格等方面各有不同,已有多个联合两类药物治疗RVO并发ME的研究报道。本文就联合用药的疗效、注药次数及使用过程中的相关注意事项等方面作一简短综述。

    Abstract:

    Retinal vein occlusion(RVO)is the most prevalent retinal vascular disease except for diabetic retinopathy. Macular edema(ME)is a common complication of RVO which is the major causation of vision loss. The pathogenesis of ME is associated with vascular endothelial growth factor(VEGF)which induced by ischemia and hypoxia after venous obstruction and destruction of blood-retinal barrier caused by inflammation. Therefore, intravitreal injection of anti-VEGF medications or corticosteroids is the most common in the clinical treatment. Due to the two medicines have different react mechanism, duration of efficacy, side effects, and prices etc. There are several researches reported that the combination of two medications in order to treat ME secondary to RVO. This essay is a brief overview of the combination therapies' efficacy, the time of injections and relevant precautions during the therapy process.

    参考文献
    相似文献
    引证文献
引用本文

李果,陈颖,严宏.视网膜静脉阻塞并发黄斑水肿的联合药物治疗进展.国际眼科杂志, 2019,19(2):252-255.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2018-11-22
  • 最后修改日期:2018-12-25
  • 录用日期:
  • 在线发布日期: 2019-01-17
  • 出版日期:
文章二维码